Locafy Limited - Ordinary Share (LCFY)
Live price chart, market sentiment, and community perspectives for Locafy Limited - Ordinary Share (NASDAQ: LCFY).
Live price chart, market sentiment, and community perspectives for Locafy Limited - Ordinary Share (NASDAQ: LCFY).
On our micro-cap desk, LCFY presents a classic dichotomy. On one hand, you have genuine operational progress, evidenced by the 31% revenue growth and deep expansion into the U.S. insurance and home services sectors via State Farm and Experience.com partnerships. On the other hand, the market capitalization sits under $5 million with a negative profit margin of nearly 78%. While insider transactions like the COO buying shares at $4.20 offer a vote of confidence, the reality of maintaining Nasdaq compliance following filing delinquency notices keeps our risk committee extremely cautious about liquidity and dilution risks from their $100M shelf registration.
When analyzing LCFY's valuation metrics for prospective modeling, our tech-services team zeroes in on the operational transition to AEO subscription services. Their databases—including Hotfrog, AussieWeb, and SuperPages—provide the foundational traffic, but the core thesis relies on monetizing the Localizer SaaS product. When stress-testing their balance sheet against their total cash position of $1.44 million and current ratio of 1.38, any investment protocol must factor in whether their accelerating top-line growth can outpace cash burn before they lean heavily on their ATM facility.
From a quantitative risk perspective, LCFY’s trading profile is defined by extreme illiquidity and micro-capitalization volatility. With an average daily volume around 14.54K shares and days when volume drops to near zero, standard technical indicators are frequently distorted. Short interest has collapsed by over 90% since August 2025 down to just 308 shares, meaning bearish institutional bets are virtually non-existent, but this also strips away any short-squeeze mechanics. Investors must weigh the 1-year return of 40.27% against the trailing return on equity of -69.51% and an EBITDA loss exceeding $1 million.
Explore plasma cleansing, somatic organ swaps, and BCI.